The Ozempic and Wegovy labels give semaglutide an elimination half-life of approximately 1 week.[1][2] After an injection, the labels say the highest concentration is reached 1 to 3 days after the dose, and the Ozempic label says steady state is reached after 4 to 5 weeks of weekly dosing.[1]

These figures come from section 12.3 (Pharmacokinetics) of each prescribing information, read on DailyMed on 20 November 2026. They describe averages from studies, not any one person, and they are not a guide to timing or skipping doses.

What the labels report

FigureOzempic labelWegovy label
Elimination half-lifeApproximately 1 weekApproximately 1 week
Time to maximum concentration (injection)1 to 3 days after the dose1 to 3 days after the dose
Time to maximum concentration (tablets)Not on this label1 hour after the dose
Time to steady state4 to 5 weeks of once-weekly dosingNot stated as a time
Still present after the last dose“about 5 weeks”“about 5 to 7 weeks” after the last injected 2.4 mg or 7.2 mg dose, or oral 25 mg dose

In the Ozempic label’s words: “With an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for about 5 weeks after the last dose.”[1] The Wegovy label says the same of its higher doses, with “about 5 to 7 weeks”.[2]

What a half-life means

A half-life is the time it takes for an amount to fall by half. After one half-life, half is left. After two, a quarter. After five, about 3%. The chart shows that halving for a single amount, with one half-life drawn as 1 week to match the label’s round figure.

Illustration: a single amount halving once a weekAn illustration of halving: 100% at the start, then 50, 25, 12.5, 6.25, 3.1 and 1.6% after each further half-life. It is not a prediction of anyone’s levels.0%50%100%100%050%125%212.5%36.25%43.1%51.6%6Weeks after a single dose (one half-life = 1 week)
Illustration only: what “half-life” means, drawn as a single amount halving at a fixed rate. It ignores absorption, repeated doses and differences between people, so it is not a prediction of anyone’s levels and not a guide to timing, delaying or skipping doses.

The same numbers as a table:

Half-lives passedWeeks (at 1 week each)Share of the starting amount
00100%
1150%
2225%
3312.5%
446.25%
553.1%
661.6%

This is plain halving, nothing more. It leaves out absorption (the labels put the peak 1 to 3 days after an injection, not at the moment of the dose), the effect of one weekly dose landing on top of the last, and the differences between people. So it cannot tell you what level anyone has on a given day. The “about 5 weeks” in the Ozempic label lines up with roughly five halvings, which is why it is shown here.

Steady state

The Ozempic label says: “Steady-state exposure is achieved following 4 to 5 weeks of once-weekly administration.”[1] Steady state is the point where, with a dose every week, the level follows the same pattern from one week to the next. The labels give the half-life and the once-weekly schedule as separate facts; this page does not draw conclusions from one about the other.

What the half-life is not

  • It is not a missed-dose rule. Each label has its own: Ozempic says to take a missed dose within 5 days, otherwise skip it; Wegovy’s injection rule depends on whether the next dose is more or less than 2 days away.[1][2]
  • It is not a reason to change the interval or to stop and restart. Those are the prescriber’s decisions.
  • It is not a reading of your own levels. Nothing on this page can tell you that.

For the full missed-dose wording and the other label facts, see the Ozempic and Wegovy label pages, and Ozempic vs Wegovy. For how semaglutide’s figures sit next to tirzepatide’s, see semaglutide vs tirzepatide and tirzepatide half-life. The semaglutide calculator covers vial arithmetic.

A weekly dose that keeps to its day is what the label schedule assumes. Kept, the iPhone app this site belongs to, sends the reminder and logs the dose in one tap.

Last checked against the labels: 20 November 2026.

Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Kept is independent and not affiliated with, endorsed by or sponsored by Novo Nordisk A/S.